Chen-Yang Tao
Overview
Explore the profile of Chen-Yang Tao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu G, Tang Z, Chu T, Wang B, Chen S, Tao C, et al.
Signal Transduct Target Ther
. 2025 Jan;
10(1):25.
PMID: 39837814
Serine arginine-rich splicing factor 1 (SRSF1) is a key oncogenic splicing factor in various cancers, promoting abnormal gene expression through post-translational regulation. Although the protumoral function of SRSF1 is well-established,...
2.
Tao C, Wu X, Song S, Tang Z, Zhou Y, Tian M, et al.
Cell Oncol (Dordr)
. 2024 Apr;
47(4):1391-1403.
PMID: 38607517
Purpose: GPX8, which is found in the endoplasmic reticulum lumen, is a member of the Glutathione Peroxidases (GPXs) family. Its role in hepatocellular carcinoma (HCC) is unknown. Methods: Immunohistochemical staining...
3.
Zhou P, Zhou C, Gan W, Tang Z, Sun B, Huang J, et al.
Commun Biol
. 2023 Nov;
6(1):1181.
PMID: 37985711
Primary liver cancer (PLC) poses a leading threat to human health, and its treatment options are limited. Meanwhile, the investigation of homogeneity and heterogeneity among PLCs remains challenging. Here, using...
4.
Qu W, Tian M, Lu H, Zhou Y, Liu W, Tang Z, et al.
Hepatol Int
. 2023 Apr;
17(4):927-941.
PMID: 37031334
Background And Purpose: Tumor recurrence after liver transplantation (LT) impedes the curative chance for hepatocellular carcinoma (HCC) patients. This study aimed to develop a deep pathomics score (DPS) for predicting...
5.
Zhu G, Tang Z, Huang R, Qu W, Fang Y, Yang R, et al.
Cell Discov
. 2023 Mar;
9(1):25.
PMID: 36878933
Hepatocellular carcinoma (HCC) is an immunotherapy-resistant malignancy characterized by high cellular heterogeneity. The diversity of cell types and the interplay between tumor and non-tumor cells remain to be clarified. Single...
6.
Qu W, Ding Z, Qu X, Tang Z, Zhu G, Fu X, et al.
BJS Open
. 2022 Sep;
6(5).
PMID: 36125345
Background: Combination conversion therapies afforded curative surgery chance for initially unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the conversion rate and clinical outcomes of a first-line conversion regimen...
7.
Qu W, Tian M, Qiu J, Guo Y, Tao C, Liu W, et al.
Front Oncol
. 2022 Sep;
12:968202.
PMID: 36059627
Background: Postoperative recurrence impedes the curability of early-stage hepatocellular carcinoma (E-HCC). We aimed to establish a novel recurrence-related pathological prognosticator with artificial intelligence, and investigate the relationship between pathological features...
8.
Zhu G, Liu W, Tang Z, Qu W, Fang Y, Jiang X, et al.
Mol Oncol
. 2021 Sep;
16(2):549-561.
PMID: 34543520
We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC). Plasma-free DNA, germline DNA, and...
9.
Zhou Y, Song S, Tian M, Tang Z, Wang H, Fang Y, et al.
J Immunother Cancer
. 2021 Aug;
9(8).
PMID: 34413167
Background: Hepatocellular carcinoma (HCC) is characterized by inflammation and immunopathogenesis. Accumulating evidence has shown that the cystathionine β-synthase/hydrogen sulfide (CBS/HS) axis is involved in the regulation of inflammation. However, roles...
10.
Liu W, Tian M, Tao C, Tang Z, Zhou Y, Song S, et al.
BMC Cancer
. 2020 Jul;
20(1):642.
PMID: 32650743
Background: The prognosis of patients with combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CHC) is usually poor, and effective adjuvant therapy is missing making it important to investigate whether these patients...